Safety Profile of the Concomitant Use of Atorvastatin and Cyclosporine in Renal Transplant Recipients
Die Pharmazie · 01.05.2023 · 78 (5)
DOI: 10.31083/ph.2023.2582 ↗Kurz gefasst
Fachartikel in der Zeitschrift Die Pharmazie, online erschienen am 01.05.2023. Verfasst von R. Harabayashi und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Cyclosporine (CyA) and atorvastatin (AT) are often administered concomitantly to treat dyslipidemia in renal transplant recipients. However, CyA greatly increases the plasma concentration of AT; therefore, concomitant use might increase the frequency of statin-induced adverse effects. The aim of this study was to investigate whether concomitant use of CyA and AT increases intolerance of the latter agent in Japanese renal transplantation recipients. We performed a retrospective cohort analysis of renal transplant recipients aged 18 years and older who had concomitantly received AT and CyA, or tacrolimus (Tac) therapy. We defined statin intolerance as a decrease in dose or discontinuation of AT due to adverse effects. We evaluated the incidence of statin intolerance in concomitant therapy with CyA for 100 days after the initial administration of AT in comparison with Tac. A total of 144 renal transplant recipients who received AT and CyA, or Tac between January 2013 and December 2019 were included. There was no statistical difference in the incidence of statin intolerance in both the CyA (1.8%; 1/57 patients) and Tac (3.4%; 3/87 patients) groups. Concomitant use of CyA and AT might not increase the incidence of statin intolerance in Japanese renal transplant recipients.
Zitieren
APA
Harabayashi, R., Takahashi, M., Takahashi, K., Sugimoto, T., Uchida, J., Nakamura, Y., & Nagayama, K. (2023). Safety Profile of the Concomitant Use of Atorvastatin and Cyclosporine in Renal Transplant Recipients. Die Pharmazie, 78(5). https://doi.org/10.31083/ph.2023.2582
Vancouver
Harabayashi R, Takahashi M, Takahashi K, Sugimoto T, Uchida J, Nakamura Y, et al. Safety Profile of the Concomitant Use of Atorvastatin and Cyclosporine in Renal Transplant Recipients. Die Pharmazie. 2023;78(5). doi:10.31083/ph.2023.2582
BibTeX
@article{Harabayashi2023,
author = {Harabayashi, R. and Takahashi, M. and Takahashi, K. and Sugimoto, T. and Uchida, J. and Nakamura, Y. and Nagayama, K.},
title = {Safety Profile of the Concomitant Use of Atorvastatin and Cyclosporine in Renal Transplant Recipients},
journal = {Die Pharmazie},
year = {2023},
volume = {78},
number = {5},
doi = {10.31083/ph.2023.2582}
}
EUVIMED